Why the study?
Does oral apelin administration improve glucose utilisation and treat metabolic disorders?
Does oral apelin administration improve glucose utilisation and treat metabolic disorders?
Oral apelin administration targets intestine-hypothalamus communication to control glucose metabolism, presenting a novel potential treatment for metabolic disorders.
Offers a potential new metabolic target; leaves open translation from animal models to human trials.
Here, we identify a novel mode of communication between the intestine and the hypothalamus that controls glucose utilisation. Moreover, our data identified oral apelin administration as a novel potential target to treat metabolic disorders.
No takes yet. Share an insight, caveat, or question.
Fournel et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: